scispace - formally typeset
A

Anja Feldmann

Researcher at Max Planck Society

Publications -  368
Citations -  18932

Anja Feldmann is an academic researcher from Max Planck Society. The author has contributed to research in topics: The Internet & Antigen. The author has an hindex of 67, co-authored 340 publications receiving 17422 citations. Previous affiliations of Anja Feldmann include Saarland University & AT&T.

Papers
More filters
Proceedings Article

On the impact of variability on the buffer dynamics in IP networks

TL;DR: The main objective of this paper is to demonstrate in the context of a simple TCP/IPbased network that depending on the underlying assumptions about the inherent nature of the variability of network traffic, very different conclusions can be derived for a number of well-studied and apparently well-understood problems in the areas of traffic engineering and management.
Proceedings ArticleDOI

Demystifying the Messaging Platforms' Ecosystem Through the Lens of Twitter

TL;DR: It is shown that Twitter is a rich source for discovering public groups in the different messaging platforms, group URLs from messaging platforms are ephemeral, and the considered messaging platforms expose personally identifiable information, with such leaks being more prevalent on WhatsApp than on Telegram and Discord.
Proceedings ArticleDOI

A Multi-perspective Analysis of Carrier-Grade NAT Deployment

TL;DR: This work develops a methodology to detect the existence of hosts behind CGNs by extracting non-routable IP addresses from peer lists the authors obtain by crawling the BitTorrent DHT, and complements this approach with improvements to the Netalyzr troubleshooting service, enabling it to determine a range of indicators of CGN presence.
Journal ArticleDOI

A year in lockdown: how the waves of COVID-19 impact internet traffic

TL;DR: In this paper, the impact of the first year of the COVID-19 pandemic on Internet traffic was analyzed in order to characterize how traffic and application demands change, to describe the "new normal", and explain how the Internet reacted during these unprecedented times.
Journal ArticleDOI

Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab®.

TL;DR: In principle, both the nb- and scFv-based TM formats are able to redirect UniCAR T cells to eliminate EGFR-expressing tumor cells in an antigen-specific and TM-dependent manner, however, the scFV-based αEGFR TM was significantly superior to the nB-basedTM especially with respect to lysis of tumor cells.